Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
86pct
48d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Food and Drug Administration Safety and Landmark Advancements Act of 2022 or the FDASLA Act of 2022 This bill modifies Food and Drug Administration (FDA) authority to collect certain fees. It also expands FDA authority to regulate certain products, including cosmetics. Among other provisions, the bill reauthorizes FDA authority to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts; establishes that certain requirements related to obtaining market approval for a new drug or a biosimilar may be satisfied using alternatives to animal testing, such as in vitro tests; authorizes the FDA to require that certain drugs be dispensed with a safe disposal system even if the system does not render a drug nonretrievable (current law requires such a system to render the drug nonretrievable); establishes time lines for the FDA to respond to requests to determine whether a drug is a therapeutic equivalent to an approved drug; modifies the accelerated process for approving products for a serious or life-threatening disease or condition and establishes an intra-agency coordinating council to ensure consistent and appropriate use of the process; requires additional regulation of cosmetics, including by requiring manufacturers to register manufacturing facilities and each cosmetic product with the FDA; requires dietary supplement manufacturers to provide to the FDA certain information, including a list of all ingredients, about each dietary supplement that it markets; requires an in vitro clinical test to receive FDA premarket approval or a technology certification (or be otherwise exempted) before being introduced into interstate commerce; and requires the FDA to temporarily relax certain premarket requirements for a manufacturer that intends to market a new infant formula.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Murray with an amendment in the nature of a substitute. Without written report.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2024 · first_quarter · Food Industry (safety, labeling, etc.)
To explore the implications from mandatory dietary supplement product listing provisions (as previously included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348)); to explore the role and needs of small businesses for market entry in the dietary supplement channel; to explore health savings accounts / flexible spending accounts in relation to dietary supplement products.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Government Issues
Paper product supply chain issues Prescription Drug Paper Inserts S.4348 FDASLA Act of 2022, H.R. 7667, Food and Drug Amendments of 2022 H.R. 8781, Ensuring Accurate Postal Rates FDA rider on paper inserts for prescription drugs in H.R. 2617, the Consolidated Appropriations Act (FY23 Omnibus)
Client expense: $690,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2024 · first_quarter · Government Issues
Paper product supply chain issues Prescription Drug Paper Inserts S.4348 FDASLA Act of 2022, H.R. 7667, Food and Drug Amendments of 2022 H.R. 8781, Ensuring Accurate Postal Rates FDA rider on paper inserts for prescription drugs in H.R. 2617, the Consolidated Appropriations Act (FY23 Omnibus)
Client expense: $930,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2023 · third_quarter · Government Issues
Paper product supply chain issues Prescription Drug Paper Inserts S.4348 FDASLA Act of 2022, H.R. 7667, Food and Drug Amendments of 2022 H.R. 8781, Ensuring Accurate Postal Rates FDA rider on paper inserts for prescription drugs in H.R. 2617, the Consolidated Appropriations Act (FY23 Omnibus)
Client expense: $570,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2023 · fourth_quarter · Government Issues
Paper product supply chain issues Prescription Drug Paper Inserts S.4348 FDASLA Act of 2022, H.R. 7667, Food and Drug Amendments of 2022 H.R. 8781, Ensuring Accurate Postal Rates FDA rider on paper inserts for prescription drugs in H.R. 2617, the Consolidated Appropriations Act (FY23 Omnibus)
Client expense: $930,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
| S 4378 |
117th |
| Related bill |
| S 4303 | 117th | Related bill |
| S 4302 | 117th | Related bill |
| S 4288 | 117th | Related bill |
| S 4152 | 117th | Related bill |
| S 2952 | 117th | Related bill |
| S 2628 | 117th | Related bill |
| HR 9329 | 117th | Related bill |
| HR 7679 | 117th | Related bill |
| HR 7658 | 117th | Related bill |
| HR 7640 | 117th | Related bill |
| HR 7035 | 117th | Related bill |
2023 · fourth_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to COVID 19 funding for BARDA; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Food Industry (safety, labeling, etc.)
To explore the implications from mandatory dietary supplement product listing provisions (as previously included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348)); to explore the role and needs of small businesses for market entry in the dietary supplement channel; to explore health savings accounts / flexible spending accounts in relation to dietary supplement products.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Government Issues
Paper product supply chain issues Prescription Drug Paper Inserts S.4348 FDASLA Act of 2022, H.R. 7667, Food and Drug Amendments of 2022 H.R. 8781, Ensuring Accurate Postal Rates FDA rider on paper inserts for prescription drugs in H.R. 2617, the Consolidated Appropriations Act (FY23 Omnibus)
Client expense: $570,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2023 · third_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to COVID 19 funding for BARDA; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Food Industry (safety, labeling, etc.)
To explore the implications from mandatory dietary supplement product listing provisions (as previously included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348)); to explore the role and needs of small businesses for market entry in the dietary supplement channel; to explore health savings accounts / flexible spending accounts in relation to dietary supplement products.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA)
2023 · second_quarter · Food Industry (safety, labeling, etc.)
To explore the implications from mandatory dietary supplement product listing provisions (as previously included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348)); to explore the role and needs of small businesses for market entry in the dietary supplement channel.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA)
2023 · second_quarter · Government Issues
Paper product supply chain issues Prescription Drug Paper Inserts S.4348 FDASLA Act of 2022, H.R. 7667, Food and Drug Amendments of 2022 H.R. 8781, Ensuring Accurate Postal Rates FDA rider on paper inserts for prescription drugs in H.R. 2617, the Consolidated Appropriations Act (FY23 Omnibus)
Client expense: $640,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2023 · second_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Medical/Disease Research/Clinical Labs
H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.1730/S.670, Speeding Therapy Access Today Act; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Pharmacy
Legislation regarding drug pricing, value, and reimbursement; H.R.3, Elijah Cummings Lower Drug Costs Now Act, and related Senate legislation; H.R.19, Lower Costs, More Cures Act of 2021; H.R.5376 - Build Back Better Act and Inflation Reduction Act - P.L. 117-169, issues related to drug policies and access to therapies for patients with rare diseases; H.R.1629, Fairness in Orphan Drug Exclusivity Act; H.R.7506, legislation to revolutionize education, diagnoses, and treatment of rare kidney diseases; H.R.7667, the Food and Drug Amendments of 2022 - provisions concerning accelerated approval, orphan drugs; S.4348, Food and Drug Administration Safety and Landmark Advancements Act of 2022 - provisions concerning accelerated approval, orphan drugs; H.R.6963, Accelerated Approval Integrity Act, a bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for post-approval studies for drugs approved using accelerated approval, and for other purposes; H.R.2617, the Consolidated Appropriations Act, 2023.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Health Issues
Mainstreaming Addiction Treatment Act (S. 445/H.R. 1384), all provisions related to removing the waiver requirement for health care providers to prescribe buprenorphine for opioid use disorder. Improving Access to Remote Behavioral Health Treatment Act of 2019, all provisions related to amending regulations for the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and allowing community mental health centers to register to practice telemedicine. Medication Access and Training Expansion Act (H.R. 2067), all provisions related to requiring physicians and other prescribers of controlled substances to complete training on treating and managing patients with substance use disorders. CONNECT for Health Act of 2023, all provisions related to expanding access to telehealth services. Telemental Health Care Access Act of 2021 (S. 2061), all provisions related to ensuring coverage of mental health services furnished through telehealth. Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708/S. 168), all provisions related to temporary authorization of in-person and telehealth services. Mental Health Services for Students Act of 2021 (H.R. 721/S. 1841), all provisions related to school-based mental health services. Elementary and Secondary School Counseling Act (H.R. 6214/S. 3356), all provisions related to awarding grants to increase access to school-based, mental health services. Opioid Treatment Access Act of 2022 (H.R. 6279), all provisions related to authorizing a study on certain exemptions for treatment of opioid use disorder through opioid treatment programs. 9-8-8 Implementation Act of 2022 (H.R. 7116), all provisions related to providing for improvements in the implementation of the National Suicide Prevention Lifeline, and for other purposes. 9-8-8 and Parity Assistance Act of 2022 (H.R.7232), all provisions related to providing for improvements in the implementation of the National Suicide Prevention Lifeline, and for other purposes. Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act (S. 586), all provisions related to establishing separate payments for certain non-opioid treatments under the Medicare prospective payment system for hospital outpatient department services and the payment system for ambulatory surgical center services Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348), all provisions related to addressing substance use disorders and the safe disposal of opioids. Telemental Health Access to Care Act (S.2061/H.R. 4058), all provisions related to intended to increase access to tele-mental health care and telehealth. Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R. 7666), all provisions related to reauthorizations, expansions, and modifications of programs, grants, and activities that focus on mental and behavioral health. Advancing Telehealth Beyond COVID-19 Act of 2021 (H.R.4040), all provisions related to extending telehealth flexibilities under the Medicare program Expanding Access to Mental Health Training Act (S. 4461), all provisions related to reauthorizing grants for training teachers and other school personnel to recognize the symptoms of childhood and adolescent mental health disorders. Behavioral Health Network and Directory Improvement Act (S. 5093), all provisions related to protect patients and improve the accuracy of provider directory information by eliminating ghost networks.
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Communications Commission (FCC), Federal Reserve System, HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
- Issues Related to Data Privacy and Security - Diagnostic and medical device regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2021 (S.2209,H.R.4128) and the Verifying Accurate Leading-edge IVCT Development Act of 2022 as included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348) and the Consolidated Appropriations Act, 2023 (P.L. 117-328) - Cancer Moonshot
Client expense: $100,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Government Issues
Paper product supply chain issues Prescription Drug Paper Inserts S.4348 FDASLA Act of 2022, H.R. 7667, Food and Drug Amendments of 2022 H.R. 8781, Ensuring Accurate Postal Rates FDA rider on paper inserts for prescription drugs in H.R. 2617, the Consolidated Appropriations Act (FY23 Omnibus)
Client expense: $540,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
2023 · first_quarter · Health Issues
Prescription drug pricing. H.R.6 - SUPPORT for Patients and Communities Act. Awareness of outcomes data and the need for training on all medication assisted treatment. H.R.7667/S.4348 - Prescription Drug User Fee Agreement Reauthorization. Implementation of Inflation Reduction Act of 2022.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
Issues related to MDUFA implementation Issues related to H.R. 7667, Food and Drug Amendments of 2022 Issues related to S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act Issues relating to FDA Covid-19 Response Issues relating to the medical product supply chain Issues relating to S. 3799, PREVENT Pandemics Act Issues related to CURES 2.0 Issues related to medical device sterilization and the use of ethylene oxide to sterilize medical devices Issues related to the Valid Act of 2021 - H.R. 4128/S.2209 Issues related to cyber security including H.R. 7084/ S. 3983, PATCH Act
Client expense: $300,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Food Industry (safety, labeling, etc.)
To clarify the regulatory uncertainty of the hemp-derived cannabidiol ingredient; to explore the implications from mandatory dietary supplement product listing provisions (as previoulsy included in the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (S.4348)); to explore the role and needs of small businesses for market entry.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA)
2022 · third_quarter · Health Issues
Issues related to FDA and drug development, Accelerated Approval Pathway; H. R. 5375- Inflation Reduction Act of 2022, issues related to prescription drugs; H.R. 7667 and S.4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA Act), issues related to Prescription Drug User Fee Act (PDUFA)
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act H.R. 6000, the CURES 2.0 Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, supply chain. health disparities, raising awareness of Cystic Fibrosis, appropriation for the Department of Health and Human Services, PDUFA, Sunshine Act, orphan drugs, 340B, Innovation, EXPERT, Non-interference, drug development policies, drug pricing, transparency
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act H.R. 6000, the CURES 2.0 Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, supply chain. health disparities, raising awareness of Cystic Fibrosis, appropriation for the Department of Health and Human Services, PDUFA, Sunshine Act, orphan drugs, 340B, Innovation, EXPERT, Non-interference, drug development policies, drug pricing, transparency
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act H.R. 6000, the CURES 2.0 Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act H.R.2617, Consolidated Appropriations Act, 2023 importation, supply chain integrity, 304b, orphan drugs, newborn screening, expanded access, priority review, transparency, drug shortages, drug pricing, insulin, international reference pricing, user fee reauthorization
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act H.R. 6000, the CURES 2.0 Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 prescription drug importation, import safety, supply chain integrity, innovation, 304B, transparency, importation, non-interference, user fee reauthorization
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 Medication affordability and access, general diabetes prevention, obesity
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act H.R. 4521, America COMPETES Act S. 2209, Verifying Accurate Leading-edge IVCT Development (VALID) S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 510K reform, imaging policy, medical device user fee reauthorization and all related policies, mobile medical apps, device regulation, Innovation, service, radiopharmaceuticals, coverage decisions, cybersecurity
Client expense: Not reported · Firm income: $80,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 innovation, non-interference, 340B, Hepatitis C, HPV, Shingles, anti-microbial resistance, transparency, Pandemic All Hazards Preparedness Act reauthorization, drug pricing, anti-microbial resistance, transparency, vaccines
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act H.R. 4521, America COMPETES Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 non-interference, dormant therapies, drug shortages, prescription drug access and affordability, transparency, insulin policy, authorized generics, 340B
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 drug safety, prescription drug abuse, drug pricing
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
S. 3799 PREVENT Pandemics Act S. 1260 United States Innovation and Competition Act H.R. 4521 America COMPETES Act of 2022 S. 4348, FDA Safety and Landmark Advancements Act 2022 H.R.2617, Consolidated Appropriations Act, 2023 General issues related to drug shortages, strategic national stockpile, COVID-19, drug cost oversight, domestic manufacturing of pharmaceutical/medical products, the Public Health Services Act
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 Pharmaceutical access and affordability, Ryan White, PEPFAR, 340B, HCV Screening, drug pricing and access, HIV, HCV, oncology, coronavirus therapeutics, FDA user fees
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 drug pricing and access, transparency, covid, 340B, drug safety
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 2209, Verifying Accurate Leading-edge IVCT Development (VALID) S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 companion diagnostics, testing, innovation, surprise billing implementation
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 prescription drug access and affordability, pricing, transparency, user fee reauthorization
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Pharmacy
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 drug safety, prescription drug importation, import safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, innovation, transparency
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R. 5376, the Inflation Reduction Act H.R.2617, Consolidated Appropriations Act, 2023 prescription drug pricing, prescription drug access and affordability, pricing, transparency, user fees
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act H.R. 4521, America COMPETES Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 FDA related issues, diagnostics, pandemic preparedness, health IT, opioid safety, anti-microbial resistance, hazardous drug safety, VA procurement, medical technology regulation, artificial intelligence, cybersecurity, privacy, medication safety & drug diversion, ESRD, coronavirus response, Operation Warp Speed, COVID-19 testing, user fees
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · fourth_quarter · Pharmacy
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 Drug coverage & reimbursement, vaccination, user fees, no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R. 5376, the Inflation Reduction Act H.R.2617, Consolidated Appropriations Act, 2023 340B, Biosimilars, Orphan drugs, prescription drug access & reimbursement, FDA issues, transparency
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 opioids, childhood cancer, vaccination, Affordable Care Act, market stabilization, access and coverage, LDT regulation, smoking cessation, Prescription drug pricing and access, Vaping and e-cigarettes
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2022 · fourth_quarter · Health Issues
H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023 340B, non-interference, importation, Puerto Rico, transparency, prescription drug pricing and access, beneficiary access
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Medicare/Medicaid
H.R. 1384, the Mainstreaming Addiction Treatment Act S.445, the Mainstreaming Addiction Treatment Act H.R. 2503, the Social Determinants Accelerator Act S. 3039, the Social Determinants Accelerator Act H.R. 3517, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 3932, the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act S. 2076, the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act HR 4040, Advancing Telehealth Beyond COVID-19 Act H.R. 4521, the America Creating Opportunities to Meaningfully Promote Excellence in Technology, Education, and Science (COMPETES) Act H.R. 6000, Cures 2.0 Act H.R. 6072, the Leveraging Integrated Networks in Communities (LINC) to Address Social Needs Act S. 509, the Leveraging Integrated Networks in Communities (LINC) to Address Social Needs Act H.R. 6087, the Improving Access to Workers Compensation for Injured Federal Workers Act H.R. 6883, Continuing Appropriations and Ukraine Supplemental Appropriations Act H.R.7008, Pre-approval Information Exchange Act H.R. 7353, the Telehealth Benefit Expansion for Workers Act H.R. 7503, Hospital Inpatient Services Modernization Act S. 3792, Hospital Inpatient Services Modernization Act H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act H.R. 7667, Food and Drug Amendments of 2022 H.R. 8152, American Data Privacy and Protection Act H.R. 8188, the Saving Access to Laboratory Services Act S. 4449, the Saving Access to Laboratory Services Act S. 3799, PREVENT Pandemics Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Health Issues
H.R. 1384, the Mainstreaming Addiction Treatment Act S.445, the Mainstreaming Addiction Treatment Act H.R. 2503, the Social Determinants Accelerator Act S. 3039, the Social Determinants Accelerator Act H.R. 3517, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act H.R. 3932, the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act S. 2076, the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act HR 4040, Advancing Telehealth Beyond COVID-19 Act H.R. 4521, the America Creating Opportunities to Meaningfully Promote Excellence in Technology, Education, and Science (COMPETES) Act H.R. 6000, Cures 2.0 Act H.R. 6072, the Leveraging Integrated Networks in Communities (LINC) to Address Social Needs Act S. 509, the Leveraging Integrated Networks in Communities (LINC) to Address Social Needs Act H.R. 6087, the Improving Access to Workers Compensation for Injured Federal Workers Act H.R. 6883, Continuing Appropriations and Ukraine Supplemental Appropriations Act H.R.7008, Pre-approval Information Exchange Act H.R. 7353, the Telehealth Benefit Expansion for Workers Act H.R. 7503, Hospital Inpatient Services Modernization Act S. 3792, Hospital Inpatient Services Modernization Act H.R. 7666, the Restoring Hope for Mental Health and Well-Being Act H.R. 7667, Food and Drug Amendments of 2022 H.R. 8152, American Data Privacy and Protection Act H.R. 8188, the Saving Access to Laboratory Services Act S. 4449, the Saving Access to Laboratory Services Act S. 3799, PREVENT Pandemics Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2022 · third_quarter · Environment/Superfund
Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Consumer Issues/Safety/Products
Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Proposals to reform FDA authority and personal care products regulatory system. Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348). Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill. Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE